Neuvera has launched a two-step skincare bundle called the Skin Lift & Repair Routine, pairing two moisturizer textures built on the company's patented Peptide G63 technology, according to a company press release issued October 15.

The products are PeptiLIFT, described as the lightweight daily option formulated to support a firmer, smoother-looking finish, and PeptiPROTECT, the richer texture aimed at skin the company describes as dry or depleted. Peptide G63 is Neuvera's term for its signaling-peptide technology, meaning a peptide intended to interact with skin cell communication rather than sit on the surface as an occlusive.

One peptide, two textures

The design logic is the interesting part of this launch. Both moisturizers carry the same peptide and differ only in base, which lets the company sell seasonal or situational switching without reformulating the active.

"Skin does not necessarily need the same level of moisture every day or throughout the year," said Deborah Archer, MD, Neuvera's chief medical advisor, in the release. The two products can be used separately or together.

The study in the release is not about this product

Neuvera's announcement cites a 2025 randomized controlled trial published in the Journal of Cosmetic Dermatology. That pilot study enrolled 60 women aged 60 to 90, and after 12 weeks the topical peptide formulation tested was associated with improvements in skin barrier function and hydration, plus a reduction in the pro-inflammatory marker IL-8 measured in blood.

What the release does not say is that the trial tested Peptide G63 or either Neuvera product. It presents the study as "broader context" for peptide skincare generally, which is an honest framing by press-release standards, and also means the bundle itself arrives with no published data attached to it.

Who is behind it

Neuvera describes itself as a biotechnology-led skincare and wellness startup built around the patented Peptide G portfolio developed by scientist Sean Shelby. It sells direct to consumers in the United States.

Bottom line

A 60-person pilot in women aged 60 to 90 is a real result, and barrier and hydration endpoints with a measured inflammatory marker are more than most cosmetic peptide marketing can point to. It is still somebody else's formulation, and until Neuvera tests its own, the honest description of Peptide G63's evidence base is that there is not a published one yet.